Dr Lal PathLabs Limited. Q4 results show revenue rise from 499.9 to 505.2 crores, a 1.06% decrease/increase in growth. EPS also rise from ₹6.37 to ₹6.84, up by 7.38%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Dr Lal PathLabs Ltd. shared its Q4 results on Thursday. They earned 505.2 crores in revenue this quarter, but that’s more than the 499.9 crores they made last quarter. The company’s growth increased by 1.06 percent when comparing the two quarters.
In terms of profits, Dr Lal PathLabs PAT (Profit After Tax) for this quarter was 56.7 crores, up from 52.8 crores in the previous quarter. Their quarter-to-quarter growth inclined by 7.39 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹6.84, which is an increase of 7.38% from the ₹6.37 EPS in the previous quarter.
Also read: ☞ ” Asian Paints Q4FY23 Results: Consolidated PAT Rises to Rs 1,234.14 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 2058.6 crores this year (2023), which is 3.80 percent lower than last year’s total revenue of 2139.9 crores.
This year’s PAT (Profit After Tax) is 238.9 crores, which is also 30.71% lower than last year’s PAT of 344.8 crores.
The EPS (Earnings Per Share) for this year is ₹28.82, which is 30.89% less than the EPS of ₹41.70 earned last year.
Dr Lal PathLabs Share Dividend Announcement / Record Date:
The Board of Directors has declared a Final Dividend of ₹6 per Equity Share of Face Value of ₹10 each of the Company (60% of Face Value). Total Dividend for FY23 stood at ₹12 per Equity Share (Interim Dividend of ₹10 per Equity Share)
| Dividend | Record Date |
| ₹6 per Equity Share | 24/08/2023 |
The record date for the dividend has not arrived yet.
About Dr Lal PathLabs:
Based in New Delhi, Dr Lal PathLabs Limited is a provider of diagnostic and healthcare tests in India. The company specializes in offering tests on blood, urine, and other viscera of the human body.
Download Full PDF Q4 Results of Dr Lal PathLabs: Click Here
For more of the Latest News, Click Here
One thought on “Dr Lal PathLabs Q4FY23 Results: Consolidated PAT Higher at Rs 56.7 Cr”